Expert Bioanalytical Services Delivered Fast
At CipherBio, we operate as a CRO mediator, helping biotech and pharma teams access high-quality bioanalytical and research services without the complexity of managing multiple vendors. We handle the entire backend process on your behalf—sourcing, vetting, and coordinating with the best CRO laboratories worldwide to secure the most reliable and cost-effective options.
From PK, immunogenicity, and biomarker analysis to broader research and development support, we manage the workflow so you can focus on your science. Simply consult with us, and our experienced team will oversee everything—from identifying the right labs to coordinating studies—ensuring speed, quality, and efficiency from discovery through clinical development.
Our Expert Bioanalytical Services
Biomarker Analysis
Customized biomarker assay development and validation to support translational research and clinical studies.
Pharmacokinetics (PK) Analysis
Comprehensive PK studies with rapid turnaround using proprietary platforms to support drug development from discovery to Phase IV trials.
Immunogenicity Testing
Sensitive and specific immunogenicity assays to detect anti-drug antibodies and assess immune responses accurately.
Management
John Pirro
A visionary pharma operational director with expertise in over 23 speaking engagements. Works directly with executive management, driving sustainable revenue and profitability growth through cross-team leadership and a flexible change management system. Experience in identifying risks, strong communication skills in executive presentations, and written content. Has dealt with assets in complex, high-stakes environments. Has a talent for innovative problem-solving and forming strategic alliances. Excels in building and leading high-performing teams while effectively resolving conflicts and driving operational success.
Rajiv Datar
A biotech entrepreneur with 25+ years of experience creating value at the intersection of science, capital, and strategy. Across my career, I’ve raised over $90M in equity and non-dilutive capital, led teams of 200+, and advanced multiple biologics and RNA programs through CMC, IND, and clinical milestones. My leadership has resulted in M&A transactions, carve-outs, and exits exceeding $100M, consistently delivering strong returns for investors and partners.
Trained as a biochemical engineer at MIT, KTH Stockholm, and Manchester, I bring deep domain expertise in RNA therapeutics, next-gen biologics, rare diseases, and bioprocessing. What differentiates me is my ability to take early-stage or underperforming biotech ventures, restructure and reposition them, and build them into scalable, investable platforms.